PIRAMAL PHARMA share price has zoomed 6% and is presently trading at Rs 230.3.
Meanwhile, the BSE HEALTHCARE index is at 44,081.5 (down 0.3%).
Among the top gainers in the BSE HEALTHCARE index today are Sanofi India (up 0.7%) and GLAND PHARMA (up 0.7%).
ASTRAZENECA PHARMA (down 5.3%) and MAX HEALTHCARE INSTITUTE (down 4.7%) are among the top losers today.
Over the last one year, PIRAMAL PHARMA has moved up from Rs 97.0 to Rs 230.3, registering a gain of Rs 133.4 (up 137.5%).
On the other hand, the BSE HEALTHCARE index has moved up from 27,800.9 to 44,081.5, registering a gain of 58.6% during the last 12 months.
The top gainers among the BSE HEALTHCARE index stocks during this same period were Jubilant Pharmova (up 181.6%), SUVEN PHARMACEUTICALS (up 126.1%) and Glenmark Pharma (up 115.1%).
Must See: These Segments are Witnessing Incredible Growth with Modi's Push
The BSE Sensex is at 84,903.9 .
The top losers among the BSE Sensex today are Asian Paints (down 0.7%) and Nestle (down 0.6%). The most traded stocks in the BSE Sensex are HDFC Bank and Tata Steel.
In the meantime, NSE Nifty is at 25,940.5 . TATA STEEL 2% CCPS and LTIMINDTREE are among the top losers in NSE NIFTY.
Over the last 12 months, the BSE Sensex has moved up from 66,023.7 to 84,903.9, registering a gain of 18,880.2 points (up 28.6%).
PIRAMAL PHARMA net profit grew 1.7% YoY to Rs -1,110 million for the quarter ended June 2024, compared to a loss of Rs 1,130 million a year ago. Net sales rose 11.6% to Rs 19,511 million during the period as against Rs 17,489 million in April-June 2023.
For the year ended March 2024, PIRAMAL PHARMA reported 109.6% increase in net profit to Rs 178 million compared to net loss of Rs 1,865 million during FY23. Revenue of the company grew 15.4% to Rs 81,712 million during FY24.
The current Price to earnings ratio of PIRAMAL PHARMA, based on rolling 12 month earnings, stands at -768.4.
Equitymaster requests your view! Post a comment on "PIRAMAL PHARMA Gains 6%; BSE HEALTHCARE Index Down 0.3%". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!